02086nas a2200157   4500008004100000245014300041210006900184260000800253520141500261100002401676700002101700700002501721700002801746700002201774856013201796       2018                        eng d00aChemo-biological evaluation of antidiabetic activity of M entha arvensis L. and it's role in inhibition of advanced glycation end products0 aChemobiological evaluation of antidiabetic activity of M entha a  cFEB3 a<p>Background: There has been enormous curiosity in the development of alternative plant based medicines to control diabetes, oxidative stress and related disorders. One of the therapeutic approaches is to reduce postprandial release of glucose in the blood. Two key enzymes that are involved in reducing postprandial glucose are α-amylase and α-glucosidase. Mentha arvensis L. has been traditionally used by several tribes as a medicinal plant to treat various disorders. Objective: The present study was undertaken to test M. arvenisis L. for inhibition of postprandial hyperglycemia. Material and method: We performed various in vitro and in vivo tests to evaluate efficacy of M. arvenisis L. for antidiabetic activity (postprandial hyperglycemia). Results: Methanolic extract of M. arvensis L. leaves showed DPPH free radical scavenging activity (more than 78% μg/μl) and high antiglycation potential (more than 90% inhibition of AGE formation). Methanolic extract also showed remarkable inhibitory effects on α-amylase (more than 50% μg/μl) and α-glucosidase (68% μg/μl) and significant inhibition of postprandial hyperglycemia in starch induced diabetic Wistar rats. Conclusion: The non-insulin dependent antidiabetic or inhibition of postprandial hyperglycemic activity of methanolic extract of M. arvensis L. leaves was shown by using in vitro and in vivo approaches in the present study.</p>1 aAgawane, Sachin, B.1 aGupta, Vidya, S.1 aKulkarni, Mahesh, J.1 aBhattacharya, Asish, K.1 aKoratkar, Santosh  uhttps://library.ncl.res.in/content/chemo-biological-evaluation-antidiabetic-activity-m-entha-arvensis-l-and-its-role-inhibition02494nas a2200313   4500008004100000022001400041245014300055210007200198260000800270300001100278490000800289520141700297653002901714653001801743653003001761653001901791653001801810100002701828700002101855700001701876700002201893700001801915700002201933700001901955700001901974700002101993700002202014856014402036       2025                        eng d  a0882-401000aCharacterization of novel phages KPAФ1, KP149Ф1, and KP149Ф2 for lytic efficiency against clinical MDR Klebsiella pneumoniae infections0 aCharacterization of novel phages KPAФ1 KP149Ф1 and KP149Ф2 for l  cMAY  a1074400 v2023 a<p>
	Phage therapy offers a promising approach to the increasing antimicrobial resistance of Klebsiella pneumoniae. This study highlights three novel lytic bacteriophages-KPAc1, KP149c1, and KP149c2-targeting multidrugresistant (MDR) K. pneumoniae. These phages belong to the Myoviridae and Podoviridae family and demonstrate their efficacy and stability across a wide range of temperatures (up to 60 degrees C) and pH levels (pH 4 to 11). Genomic analysis reveals that they are free from virulence, toxicity, and antimicrobial resistance genes, making them promising candidates for therapeutic use. Among these phages, KPAc1 showed the highest lytic activity with a 26.15% lysis against MDR K. pneumoniae isolates. Additionally, a phage cocktail comprising all three phages improved lytic efficacy to 32.30%. This study also examined the antimicrobial resistance profiles of K. pneumoniae isolates, emphasizing the critical need for alternative treatments. By effectively targeting resistant strains, these phages offer a potential candidacy to be used as a viable alternative or a complementary antimicrobial agent to traditional antibiotics, opening up the possibility for advanced phage-based therapies. The promising results from this study pave the way for developing new treatments that could significantly improve patient care and outcomes from the growing issue of resistant bacterial infections.</p>
10aAntimicrobial resistance10aBacteriophage10aMDR-Klebsiella pneumoniae10aPhage cocktail10aPhage therapy1 aDandekar, Shraddha, S.1 aThanikkal, Sinta1 aLondhe, Arti1 aBhutada, Pankhudi1 aSaha, Ujjayni1 aPawar, Shubhankar1 aSamson, Rachel1 aDharne, Mahesh1 aSaroj, Sunil, D.1 aKoratkar, Santosh  uhttps://library.ncl.res.in/content/characterization-novel-phages-kpa%D1%841-kp149%D1%841-and-kp149%D1%842-lytic-efficiency-against-clinical